Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
In this medfyle
Largest real-world dataset to date shows people using rituximab or JAKi for RA are more likely to experience poor COVID-19 outcomes. Explore the results here.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Annals of the Rheumatic Diseases, EULAR’s official journal, through an official agreement with BMJ.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by David S. Pisetsky, MD, PhD, Duke University Medical Center, Durham, NC USA.
Original article:
Sparks JA, Wallace ZS, Seet AM COVID-19 Global Rheumatology Alliance, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases 2021;80:1137-1146.
Copyright © 2020 BMJ Publishing Group Limited and Globalport (International) Limited. All rights reserved.
The summaries, expert commentaries and slides included in this Medfyle are co-owned by BMJ and GlobalPort (International) Limited. The original journal article is an exclusive copyright of BMJ Publishing Group Limited.
